A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
NCT00848926
First received: February 18, 2009
Last updated: June 30, 2014
Last verified: June 2014
  Purpose

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.


Condition Intervention Phase
Disease, Hodgkin
Drug: brentuximab vedotin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Resource links provided by NLM:


Further study details as provided by Seattle Genetics, Inc.:

Primary Outcome Measures:
  • Objective Response Rate by Independent Review Group [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
    Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.


Secondary Outcome Measures:
  • Complete Remission Rate by Independent Review Group [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
    Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

  • Duration of Objective Response by Kaplan-Meier Analysis [ Time Frame: up to 23.5 months ] [ Designated as safety issue: No ]
    Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.

  • Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis [ Time Frame: up to 23.5 months ] [ Designated as safety issue: No ]
    Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.

  • Progression-free Survival by Kaplan-Meier Analysis [ Time Frame: up to 23.5 months ] [ Designated as safety issue: No ]
    Time from start of study treatment to disease progression per independent review group or death due to any cause.

  • Overall Survival [ Time Frame: up to 23.5 months ] [ Designated as safety issue: No ]
    Time from start of study treatment to date of death due to any cause.

  • Adverse Events by Severity, Seriousness, and Relationship to Treatment [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
    Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

  • Hematology Laboratory Abnormalities >/= Grade 3 [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
    Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

  • Chemistry Laboratory Abnormalities >/= Grade 3 [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
    Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

  • Area Under the Curve [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

  • Maximum Serum Concentration [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

  • Time of Maximum Serum Concentration [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin


Other Outcome Measures:
  • B Symptom Resolution [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
    Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss >10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.


Enrollment: 102
Study Start Date: February 2009
Estimated Study Completion Date: August 2015
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Brentuximab vedotin Drug: brentuximab vedotin
1.8 mg/kg every 3 weeks by intravenous infusion
Other Names:
  • SGN-35
  • ADCETRIS

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with relapsed or refractory Hodgkin lymphoma who have previously received autologous stem cell transplant.
  • Histologically confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.
  • Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm as documented by spiral computed tomography.
  • At US sites patients greater than or equal to 12 years of age may be enrolled. At non-US sites patients must be greater than or equal to 18 years of age.

Exclusion Criteria:

  • Previous treatment with brentuximab vedotin.
  • Previously received an allogeneic transplant.
  • Congestive heart failure, Class III or IV, by the New York Heart Association criteria.
  • History of another primary malignancy that has not been in remission for at least 3 years.
  • Known cerebral/meningeal disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00848926

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010-3000
University of California at Los Angeles
Los Angeles, California, United States, 90095
Stanford University Medical Center
Palo Alto, California, United States, 94305
United States, Colorado
Rocky Mountain Cancer Center
Denver, Colorado, United States, 80218
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20007
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Illinois
Loyola University Medical Center Cardinal Bernardin Cancer Center
Maywood, Illinois, United States, 60153
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Weill Cornell Medical College
New York, New York, United States, 10021
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Texas
Baylor Sammons Cancer Center
Dallas, Texas, United States, 75246
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
United States, Washington
University of Washington
Seattle, Washington, United States, 98109
Belgium
UZ Gasthuisberg
Leuven, Belgium, 3000
Cliniques Universitaires UCL de Mont-Goddine
Yvoir, Belgium, 5530
Canada, British Columbia
B.C Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
France
Institut Paoli Calmettes
Marseille, France, 13273
Hospital Saint Louis
Paris, France, 75475
Centre Henri Becquerel
Rouen, France, 76038
Italy
Instituto di Ematologia ed Oncologia Medica
Bologna, Italy, 40138
Sponsors and Collaborators
Seattle Genetics, Inc.
Millennium Pharmaceuticals, Inc.
Investigators
Study Director: Eric Sievers, MD Seattle Genetics, Inc.
  More Information

Publications:
Responsible Party: Seattle Genetics, Inc.
ClinicalTrials.gov Identifier: NCT00848926     History of Changes
Other Study ID Numbers: SG035-0003, 2008-006034-10
Study First Received: February 18, 2009
Results First Received: September 15, 2011
Last Updated: June 30, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Seattle Genetics, Inc.:
Antigens, CD30
Antibody-Drug Conjugate
Antibodies, Monoclonal
Disease, Hodgkin
Hematologic Diseases
Lymphoma
monomethylauristatin E
Drug Therapy
Immunotherapy

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014